SlideShare uma empresa Scribd logo
1 de 90
NEUROMUSCULAR
  BLOCKING AGENTS
     Carlos Darcy Alves Bersot TSA.SBA
        MD RESPONSÁVEL PELO CET H.F.LAGOA
Médico Anestesiologista do Hospital Federal da Lagoa-SUS
Médico Anestesiologista do Hospital Pedro Ernesto-UERJ
Key Concepts
•Muscle relaxation does not ensure unconsciousness, amnesia, or analgesia

•Neuromuscular blocking agents are used to improve conditions for tracheal intubation, to provide
immobility during surgery, and to facilitate mechanical ventilation.

•Depolarizing muscle relaxants act as acetylcholine (ACh) receptor agonists, whereas
nondepolarizing muscle relaxants function as competitive antagonists.

•Depolarizing muscle relaxants are not metabolized by acetylcholinesterase, they diffuse away
from the neuromuscular junction and are hydrolyzed in the plasma and liver by another enzyme,
pseudocholinesterase (nonspecific cholinesterase, plasma cholinesterase, or
butyrylcholinesterase).

•With the exception of mivacurium, nondepolarizing agents are not significantly metabolized by
either acetylcholinesterase or pseudocholinesterase. Reversal of their blockade depends on
redistribution, gradual metabolism, and excretion of the relaxant by the body, or administration of
specific reversal agents (eg, cholinesterase inhibitors) that inhibit acetylcholinesterase enzyme
activity.

•Compared with patients with low enzyme levels or heterozygous atypical enzyme in whom
blockade duration is doubled or tripled, patients with homozygous atypical enzyme will have a
very long blockade (eg, 4–6 h) following succinylcholine administration.

•Succinylcholine is considered contraindicated in the routine management of children and
adolescents because of the risk of hyperkalemia, rhabdomyolysis, and cardiac arrest in children with
undiagnosed myopathies
•Normal muscle releases enough potassium during succinylcholine-induced depolarization to raise
serum potassium by 0.5 mEq/L. Although this is usually insignificant in patients with normal baseline
potassium levels, a life-threatening potassium elevation is possible in patients with burn injury,
massive trauma, neurological disorders, and several other conditions

•Doxacurium, pancuronium, vecuronium, and pipecuronium are partially excreted by the kidneys, and
their action is prolonged in patients with renal failure.

•Atracurium and cisatracurium undergo degradation in plasma at physiological pH and temperature
by organ-independent Hofmann elimination. The resulting metabolites (a monoquaternary acrylate
and laudanosine) have no intrinsic neuromuscular blocking effects


•Hypertension and tachycardia may occur in patients given pancuronium. These cardiovascular
effects are caused by the combination of vagal blockade and catecholamine release from adrenergic
nerve endings

•Long-term administration of vecuronium to patients in intensive care units has resulted in prolonged
neuromuscular blockade (up to several days), possibly from accumulation of its active 3-hydroxy
metabolite, changing drug clearance, or the development of a polyneuropathy
•Rocuronium (0.9–1.2 mg/kg) has an onset of action that approaches succinylcholine (60–90 s),
making it a suitable alternative for rapid-sequence inductions, but at the cost of a much longer
duration of action.
History of neuromuscular blocking
                      agents



• Early 1800’s – curare   • 1942 – curare used for
  discovered in use by      muscular relaxation in
  South American            general anesthesia
  Indians as arrow        • 1949 – gallamine
  poison                    discovered as a
• 1932 – West               substitute for curare
  employed curare in      • 1964 – more potent
  patients with tetanus     drug pancuronium
  and spastic disorders     synthesized
Bloqueadores Não-despolarizantes
 Curares -                 Chondrodendron e Strychnos




    Farmacologia – Texto e atlas, 4ª ed., 2003.
                                                  Strychnos toxifera
West 1932
Milestones of Neuromuscular
       Blockade in Anesthesia
•   1942 introduction of dTc in anesthesia
•   1949 Succinylcholine, gallamine metocurine introduced
•   1958 Monitoring of NMF with nerve stimulators
•   1968 Pancuronium
•   1971 introduction of TOF
•   1982 Vecuronium,Pipecurium,atracurium
•   1992 Mivacurium
•   1994 Rocuronium
•   1996 Cisatracurium
•   2000 Rapacurium introduced and removed
Aspectos Morfológicos e Funcionais
Aspectos Morfológicos e Funcionais




      Imagem da junção        Sinapse neuromuscular imagem
                                 em microscopia eletrônica
 neuromuscular em varredura
Canais Voltagem Dependentes
α 2βγδ (embrionário)
α 2βεδ (maduro)




 Only the two identical α subunits
 are capable of binding ACh
 molecules
Neuromuscular Physiology

Acetylcholine receptor channels
                                             Extrajunctional




                                                  Junctional




                                  Anesthesia 5th ed p 740
Bloqueadores Não-despolarizante
   MECANISMO DE AÇÃO




        Tubocurarine




  Potenciais de ação e potenciais de placa terminal na
      vigência de bloqueador não-despolarizante
Bloqueadores Não-despolarizante
  Margem de Segurança da Transmissão Neuromuscular
Site of Action of d-Tubocurarine

                                Nerve AP
                                Muscle AP



                                  Left Leg
                                  Muscle
                                  Stimulation


                                  Right Leg
                                  Nerve
                                  Stimulation

Right Leg Muscle Stimulation
Non-depolarizing Block




Bersot,CDA UFRJ
Bloqueadores Despolarizantes

                       succinilcolina
Bersot,cda ufrj 2002
Farmacologia da Junção Neuromuscular


Bloqueadores Não-despolarizantes
   COMPOSTOS SINTÉTICOS
              Derivados Isoquinolínicos




         Lee, (2003) Pharmacology & Therapeutics, 98:143-169
Farmacologia da Junção Neuromuscular

Bloqueadores Não-despolarizantes
   COMPOSTOS SINTÉTICOS

            Derivados Aminoesteróides




         Lee, (2003) Pharmacology & Therapeutics, 98:143-169
Farmacologia da Junção Neuromuscular


Bloqueadores Despolarizantes
Paton & Zaimis, 1949 – Decametônio e Succinilcolina




             Lee, (2003) Pharmacology & Therapeutics, 98:143-169
Succinylcholine
“Except when used for emergency tracheal
  intubation or in instances in clinical practice
  where immediate securing of the airway is
  necessary, succinylcholine is contraindicated in
  children and adolescent patients.”
Succinylcholine
Advantages                Disadvantages

Rapid onset               Hyperkalemia
                          (burns,massive
  trauma,denervation.…)
Short Duration
I.M. injection            Cardiac Dysrhythmias
                          Masseter Spasm
                          Malignant Hyperthermia
                          Myalgias
                          Prolonged effect
Succinylcholine:
          Hyperkalemic Response
Major burns, Massive trauma, Denervation injuries
prolonged immobility, sepsis.
    – normal response; approx. 0.5 mEq/L
    – not attenuated by defasciculation
    – increased extrajunctional receptors (few days to form)
Succinylcholine:
                 Myalgias

•   mechanism-speculative
•   incidence: 0.2-89%
•   young, female, early ambulation
•   severity not related to intensity of fasciculations
•   Pre-treatment with NDMR prevents fasciculations
    and may decrease myalgias
Succinylcholine:
increased intragastric pressure

  – G-E junction opens at pressures > 28cm H20
  – transient increase up to 40 cm H20
  – Defasciculate, abolishes the rise
Succinylcholine:
            intraocular pressure

     – Prevention: defasciculate, benzodiazepam,
       lidocaine,acetazolamide, deep anesth. at laryngoscopy
     – Drug of Choice? for the “Glaucoma” and “full stomach”
     – Recommendations: SUX if possible, priorize, Airway first.
     – If SUX is used: sedate and defasciculate
     – transient increase of 8mm Hg ; peaks at 2-4 min
     – due to contraction of extra-ocular muscles

•   See Vachon C. Succinylcholine and the open globe: Tracing the
    Teaching Anesthesiol 99: 220-223, 2003
Succinylcholine:
Prolonged Apnea after….

     • Etiology
     • Diagnosis
     • Management
Prolonged Apnea after Succinylcholine
             Etiology


     • Decreased Plasma Cholinesterase
       Activity
       –   Physiologic Variation
       –   Disease States
       –   Iatrogenic
       –   Genetic
Duration of Sux induced NM-block VS pChE activity




                                     Anesthesia 5th ed p 420
Plasma Cholinesterase
   (Prolonged Apnea after….)

• Disease States
   –   Hepatic Cirrhosis (reduced 50%)
   –   renal disease (50%), returns to normal after renal transplant
   –   malignancy (bronchogenic, GI)
   –   Burns
Plasma Cholinesterase
       (Prolonged Apnea after…)
• Iatrogenic
   –   echthiophate
   –   anticholinesterases
   –   pancuronium
   –   pheneizine (MAO inhibitor)
   –   glucocorticoids (estrogens)
   –   organophosphates (insecticides)
   –   cytotoxic drugs (cyclophosphamide)
Malignant Hyperthermia
              (Hyperpyrexia)
• Condition caused by a defect in the molecule
  linking muscle membrane t-tubules to the
  sarcoplasmic reticulum (ryanodine receptor).
• Uncontrolled Ca++ release from the S.R. leads to
  contracture and a rise in body core temperature.
• Succinylcholine can precipitate an attack even in
  the absence of halothane like anesthetics.
• Dantrolene blocks this inappropriate response of
  the ryanodine receptor and prevents Ca++ loss
Muscle Relaxants:
    Physio-chemical Properties
Highly Ionized at Physiol. pH
   – + charged quaternary N attracted to
      - charged cholinergic receptor
   – most contain 2 + charges (biquaternary) separated by
     varying sizes of lipophilic bridge (potency)
   – quaternary ammonium (like Ach)
Muscle Relaxants:
       Physio-chemical Properties

Highly Water Soluble/ Relatively Hydrophilic
   – easily excreted in urine
   – do not cross lipid membranes (most cells, BBB,
     placenta)
   – small volume of distribution
   – not actively metabolized by the liver
       (cytochrome P-450 enzyme system requires lipophilic
     substrates)
Pancuronium
•   Bis-quaternary Aminosteroid
•   High potency therefore slow onset
•   Long acting
•   No or slight increase on blood pressure
•   Vagolytic
•   Renal clearance
Rocuronium

Mono-quaternary aminosteroid
  –   potency, approx 1/6 that of Vecuronium
  –   fast onset (< I min with 0.8 mg/kg)
  –   intermediate duration (44 min with 0.8 mg/kg)
  –   minimal CV side effects
  –   onset and duration prolonged in elderly
  –   slight decrease in elimination in RF
Mivacurium

Bisquaternary benzylisoquinoline
  –   potency, 1/3 that of atracurium
  –   relatively slow onset 1.5 min with 0.25 mg/kg
  –   short duration 12-18 min with 0.25 mg/kg
  –   histamine release with doses 3-4X ED95
  –   hydrolyzed by pChE, recovery may be prolonged in
      some populations (e.g. atypical pChE)
Cis-Atracurium

one of the stereo isomers of atracurium (15%)
  –   3 X more potent than atracurium
  –   slow onset, intermediate duration
  –   eliminated by Hoffman degradation
  –   Laudanosine as a metabolite
  –   non-organ elimination
  –   doses of 5 X ED95 (0.05mg/kg)
       • no histamine release
       • CV stability
Rapacuronium
monoquaternary aminosteroid, analogue of
 Vecuronium
 – low potency, fast onset, short to intermediate
   duration
 – 1.5-2.0 mg/kg doses give good intubating conditions
   at 60 sec
 – duration of action, dependent on dosage and age of
   patient
 – 20 % decrease in aBP observed with 2-3 mg/kg
   doses
 – principle route of elimination may be liver as 22% is
   renal excretion.
 – introduced in 2000 in US and removed, after
   paediatric deaths (bronchospasm).
Hemodynamic Effects of d-Tubocurarine and Pancuronium

       HR                       CO




         SVR                              MAP
Effect of Potency on Onset of NMB
Effect of Dose on Onset of NMB
Hepato-Biliary Disease
Pancuronium (20% metabolized to active metabolite)
   increased Vd
   decreased plasma clearance
   prolonged elimination T1/2
A large initial dose is required to prod the same plasma conc. but
   the block will be prolonged

Vecuronium (20-30%metabolized to active metabolite)
  initial studies yielded similar results to pancuronium
  later studies show effect only with large doses
Rocuronium is excreted unchanged in the urine and bile. Biliary
  excretion (2/3) appears to the predominant route. In cirrhotic
  patients, rocuronium pharmacodynamics and elimination kinetics
  are not changed much. The prolonged onset and slightly
  prolonged recovery is explained by the larger Vd in these
  patients.
Percent of Dose Dependant
           on Renal Elimination
> 90%            60-90%              40-60%      <25%

Gallamine (97)   Pancuronium (80)    d-TC (45)   Succinylcholine
                 Pipecuronium (70)               Vecuronium (20)
                 Doxacurium (70)                 Atracurium (NS)
                 Metocurine (60)                 Mivacurium (NS)
                                                 Rocuronium
Rationale Choice of Muscle
         Relaxant:
  Cardiovascular Effects
      Tachycardia
      Bradycardia
      Hypotension
      Arrhythmias
Reversal of Neuromuscular
            Blockade
How?
• Anticholinesterases:
   – Edrophonium
   – Neostigmine


• Cholinesterase

• Removal of blocking agents
   – Org 25969 (Cylcodextrin)
      • Ring of sugars that soak up Rocuronium
              •
Anticholinesterases
Unwanted side effects
  – Autonomic
  – Nausea and vomiting
      • Neostigmine > Edrophonium ?


• Edrophonium (0.5-1.0 mg/kg) with Atropine ( 7-15
  ug/kg)
• Neostigmine (40-70 ug/kg) with Glycopyrolate
  (0.7-1.0mg)
Difficulty reversing block
•   Right dose?
•   Intensity of block to be reversed?
•   Choice of relaxant?
•   Age of patient?
•   Acid-base and electrolyte status?
•   Temperature?
•   Other drugs?
Cold patients-longer durations




                       Anesthesia 5th ed p 463
POSTOPERATIVE RESIDUAL CURARIZATION
                  ( PORC)

• common after NDMRs
• long acting > intermediate > short acting
• Assoc with respir. morbidity

• not observed in children
• monitoring decreases incidence
•   Ventilatory response to hypoxia is impaired and does
    not return to normal until TOF > 0.9
    (Ericksson et al, Anesthesiology 78: 693-699 1993)



•   Reduced Pharyngeal muscle coordination with TOF
    0.6-.08
    (Ericksson et al, Anesthesiology 87: 1035-43 1997)
Neuromuscular Transmission
Approximate Relationships of %
      receptor blockade, ST and TOF
                with NDMB
Total receptors   Single twitch, T1   Train of Four, T4   T4/T1
Blocked %         % normal            % Normal
100               0                   0
90-95             0                   0                   T1 lost
85-90             10                  0                   T2 lost
                  20                  0                   T3 lost
80-85             25                  0                   T4 lost
                  80-90               48-58               0.6-0.7
                  95                  69-79               0.7-0.75
75                100                 75-100              0.75-1.0
                  100                 100                 0.9-1.0
50                100                 100                 1.0
25                100                 100                 1.0
Monitoring Neuromuscular
          Function
• Visual/tactile assessment of evoked
  responses
• Measurement of evoked responses
     • Mechanomyography
     • Electromyography
     • Accelerometry
Monitoring Neuromuscular
         Function
            • Mechanomyography

              – Gold standard
Monitoring Neuromuscular
         Function
            • Accelerometry
Monitoring Neuromuscular
           Function
 SUPRAMAXIMAL STIMULATION

– 10-20% above current output required to stimulate all nerve
  fibers
– Minimizes influence of :temp.skin resistance and changes in
  electrode conductance
Monitoring Neuromuscular
         Function
• STIMULATION PATTERNS

    •   Single Impulse or Twitch (ST)
    •   Train of Four (TOF)
    •   Tetanus
    •   Double Burst Simulation (DBS)
    •   Post Tetantic Count (PTC)
STIMULATION
   PATTERNS
• SINGLE TWITCH

  – Onset, dependency on frequency
  – Recovery
     • Control required
     • May still have residual paralysis
STIMULATION
   PATTERNS
• TETANUS

 – 50 Hz, fade with NDMR’s
 – 100 Hz, fade without NDMR’s
 – Sensitive indicator of residual block
SIMULATION PATTERNS


 • TRAIN OF FOUR (TOF)
  – Measures continued relaxation
  – Identifies phase II block
  – No control required
  – Tolerable in awake patients
  – measurement O.7 of o.9 or
    1 ????
STMULATION PATTERNS
•   DOUBLE BURST STIMULATION

    –   Two bursts of 50Hz stimulation, separated by
        750msec
    –   Measured fade correlates with TOF
    –   Tactile and visual evaluation of response superior to
        TOF
STIMULATION PATTERNS
• POST TETANIC COUNT

  –   50 Hz for 5 sec, followed in 3 sec by ST@ 1 Hz
  –   Shouldn’t be repeated more than 6 mins
  –   Used to monitor intense block
  –   Predicts optimal time to reversal
Neuromuscular blocking
Neuromuscular blocking
Neuromuscular blocking
Neuromuscular blocking
Neuromuscular blocking
Neuromuscular blocking
Neuromuscular blocking

Mais conteúdo relacionado

Mais procurados

Sugammadex - a revolution in anaesthesia?
Sugammadex - a revolution in anaesthesia?Sugammadex - a revolution in anaesthesia?
Sugammadex - a revolution in anaesthesia?
meducationdotnet
 
Monitored anaesthesia care
Monitored anaesthesia careMonitored anaesthesia care
Monitored anaesthesia care
AnaestHSNZ
 
Dibucaine number
Dibucaine numberDibucaine number
Dibucaine number
Dr Sandeep
 
Antipyschiatric drugs and ect anaesthesia
Antipyschiatric drugs and ect   anaesthesiaAntipyschiatric drugs and ect   anaesthesia
Antipyschiatric drugs and ect anaesthesia
Arthi Rajasankar
 

Mais procurados (20)

Opioids & Their Use in Anaesthesia
Opioids & Their Use in Anaesthesia Opioids & Their Use in Anaesthesia
Opioids & Their Use in Anaesthesia
 
Skeletal muscle relaxants, Neuromuscular blocking agents, Neuromuscular blockers
Skeletal muscle relaxants, Neuromuscular blocking agents, Neuromuscular blockersSkeletal muscle relaxants, Neuromuscular blocking agents, Neuromuscular blockers
Skeletal muscle relaxants, Neuromuscular blocking agents, Neuromuscular blockers
 
Sugammadex - a revolution in anaesthesia?
Sugammadex - a revolution in anaesthesia?Sugammadex - a revolution in anaesthesia?
Sugammadex - a revolution in anaesthesia?
 
Muscle relaxant and reversal agents
Muscle relaxant and reversal agentsMuscle relaxant and reversal agents
Muscle relaxant and reversal agents
 
Thiopentone upendra
Thiopentone upendraThiopentone upendra
Thiopentone upendra
 
Dexmedetomidine A novel anesthetic agent
Dexmedetomidine A novel anesthetic agentDexmedetomidine A novel anesthetic agent
Dexmedetomidine A novel anesthetic agent
 
Dexmedetomidine
DexmedetomidineDexmedetomidine
Dexmedetomidine
 
Neuromuscular blocking agents
Neuromuscular blocking agentsNeuromuscular blocking agents
Neuromuscular blocking agents
 
Neuromuscular blockade & Reversal agents & Monitoring
Neuromuscular blockade & Reversal agents & Monitoring  Neuromuscular blockade & Reversal agents & Monitoring
Neuromuscular blockade & Reversal agents & Monitoring
 
INTRA VENOUS INDUCING AGENTS
INTRA VENOUS INDUCING AGENTS INTRA VENOUS INDUCING AGENTS
INTRA VENOUS INDUCING AGENTS
 
Remifentanil
RemifentanilRemifentanil
Remifentanil
 
Regional Blocks of the Upper Limb and Thorax RRT
Regional Blocks of the Upper Limb and Thorax RRTRegional Blocks of the Upper Limb and Thorax RRT
Regional Blocks of the Upper Limb and Thorax RRT
 
Monitored anaesthesia care
Monitored anaesthesia careMonitored anaesthesia care
Monitored anaesthesia care
 
ASRA Guidelines 4th Edition
ASRA Guidelines 4th EditionASRA Guidelines 4th Edition
ASRA Guidelines 4th Edition
 
Dibucaine number
Dibucaine numberDibucaine number
Dibucaine number
 
caudal anesthesia.pdf
caudal anesthesia.pdfcaudal anesthesia.pdf
caudal anesthesia.pdf
 
General anaesthesia (New) - drdhriti
General anaesthesia (New) - drdhriti General anaesthesia (New) - drdhriti
General anaesthesia (New) - drdhriti
 
Suxamethonium
Suxamethonium Suxamethonium
Suxamethonium
 
Muscle Relaxants
Muscle RelaxantsMuscle Relaxants
Muscle Relaxants
 
Antipyschiatric drugs and ect anaesthesia
Antipyschiatric drugs and ect   anaesthesiaAntipyschiatric drugs and ect   anaesthesia
Antipyschiatric drugs and ect anaesthesia
 

Destaque

Destaque (10)

Ryanodex,a new dantrolene formulation
Ryanodex,a new dantrolene formulation Ryanodex,a new dantrolene formulation
Ryanodex,a new dantrolene formulation
 
Succinylcholine Apnea in an Unusual Case Posted for Dentigerous Cyst Excision
Succinylcholine Apnea in an Unusual Case Posted for Dentigerous Cyst ExcisionSuccinylcholine Apnea in an Unusual Case Posted for Dentigerous Cyst Excision
Succinylcholine Apnea in an Unusual Case Posted for Dentigerous Cyst Excision
 
Baclofen low back pain | Muhammad Nizam Uddin
Baclofen low back pain | Muhammad Nizam UddinBaclofen low back pain | Muhammad Nizam Uddin
Baclofen low back pain | Muhammad Nizam Uddin
 
Centrally Acting Antispastic Drugs
Centrally Acting Antispastic DrugsCentrally Acting Antispastic Drugs
Centrally Acting Antispastic Drugs
 
Rabeprazole
RabeprazoleRabeprazole
Rabeprazole
 
Skeletal muscle relaxants
Skeletal muscle relaxantsSkeletal muscle relaxants
Skeletal muscle relaxants
 
Intrathecal baclofen
Intrathecal baclofenIntrathecal baclofen
Intrathecal baclofen
 
Rabeprazole 20 medical ppt
Rabeprazole 20 medical pptRabeprazole 20 medical ppt
Rabeprazole 20 medical ppt
 
Skeletal Muscle Relaxants
Skeletal Muscle RelaxantsSkeletal Muscle Relaxants
Skeletal Muscle Relaxants
 
Skeletal muscle relaxants - drdhriti
Skeletal muscle relaxants - drdhritiSkeletal muscle relaxants - drdhriti
Skeletal muscle relaxants - drdhriti
 

Semelhante a Neuromuscular blocking

SKELETAL_MUSCLE_RELAXANTS.ppt
SKELETAL_MUSCLE_RELAXANTS.pptSKELETAL_MUSCLE_RELAXANTS.ppt
SKELETAL_MUSCLE_RELAXANTS.ppt
Imtiyaz60
 
Skeletal Muscle R ,,oa averse effects uses
Skeletal Muscle R ,,oa averse effects usesSkeletal Muscle R ,,oa averse effects uses
Skeletal Muscle R ,,oa averse effects uses
VijayavengadamAVijay
 
skeletalmusclerelaxants.pdf
skeletalmusclerelaxants.pdfskeletalmusclerelaxants.pdf
skeletalmusclerelaxants.pdf
Imtiyaz60
 
Neuromuscular blocking drugs_and_anticholinesterases_update_
Neuromuscular blocking drugs_and_anticholinesterases_update_Neuromuscular blocking drugs_and_anticholinesterases_update_
Neuromuscular blocking drugs_and_anticholinesterases_update_
ermidebas
 
skeletalmusclerelaxants-151101095949-lva1-app6891 (1).pptx
skeletalmusclerelaxants-151101095949-lva1-app6891 (1).pptxskeletalmusclerelaxants-151101095949-lva1-app6891 (1).pptx
skeletalmusclerelaxants-151101095949-lva1-app6891 (1).pptx
chandreshmishra13
 

Semelhante a Neuromuscular blocking (20)

Neuromuscular blocking 2
Neuromuscular blocking 2Neuromuscular blocking 2
Neuromuscular blocking 2
 
Copy of skeletal muscle relaxants / dental implant courses
Copy of skeletal muscle relaxants / dental implant coursesCopy of skeletal muscle relaxants / dental implant courses
Copy of skeletal muscle relaxants / dental implant courses
 
muscle relaxants / oral surgery courses
muscle relaxants / oral surgery courses muscle relaxants / oral surgery courses
muscle relaxants / oral surgery courses
 
Skeletal muscle relaxants
Skeletal muscle relaxantsSkeletal muscle relaxants
Skeletal muscle relaxants
 
SKELETAL MUSCLE RELAXANTS
SKELETAL MUSCLE RELAXANTSSKELETAL MUSCLE RELAXANTS
SKELETAL MUSCLE RELAXANTS
 
SKELETAL_MUSCLE_RELAXANTS.ppt
SKELETAL_MUSCLE_RELAXANTS.pptSKELETAL_MUSCLE_RELAXANTS.ppt
SKELETAL_MUSCLE_RELAXANTS.ppt
 
SKELETAL_MUSCLE_RELAXANTS final.pptx
SKELETAL_MUSCLE_RELAXANTS final.pptxSKELETAL_MUSCLE_RELAXANTS final.pptx
SKELETAL_MUSCLE_RELAXANTS final.pptx
 
Skeletal Muscle R ,,oa averse effects uses
Skeletal Muscle R ,,oa averse effects usesSkeletal Muscle R ,,oa averse effects uses
Skeletal Muscle R ,,oa averse effects uses
 
skeletalmusclerelaxants.pdf
skeletalmusclerelaxants.pdfskeletalmusclerelaxants.pdf
skeletalmusclerelaxants.pdf
 
Smooth muscle relaxants
Smooth muscle relaxantsSmooth muscle relaxants
Smooth muscle relaxants
 
NMB.pptx
NMB.pptxNMB.pptx
NMB.pptx
 
Depolarising and non depolarising smr
Depolarising and non depolarising smrDepolarising and non depolarising smr
Depolarising and non depolarising smr
 
SKELETAL MUSCLE RELAXANTS
SKELETAL MUSCLE RELAXANTSSKELETAL MUSCLE RELAXANTS
SKELETAL MUSCLE RELAXANTS
 
Neuromuscular blocking drugs_and_anticholinesterases_update_
Neuromuscular blocking drugs_and_anticholinesterases_update_Neuromuscular blocking drugs_and_anticholinesterases_update_
Neuromuscular blocking drugs_and_anticholinesterases_update_
 
SKELETAL MUSCLE RELAXENT.pptx
SKELETAL MUSCLE RELAXENT.pptxSKELETAL MUSCLE RELAXENT.pptx
SKELETAL MUSCLE RELAXENT.pptx
 
Skeletal muscle relaxant
Skeletal muscle relaxantSkeletal muscle relaxant
Skeletal muscle relaxant
 
Skeletal muscle relaxants
Skeletal muscle relaxantsSkeletal muscle relaxants
Skeletal muscle relaxants
 
Skeletal muscle relaxants
Skeletal muscle relaxantsSkeletal muscle relaxants
Skeletal muscle relaxants
 
skeletalmusclerelaxants-151101095949-lva1-app6891 (1).pptx
skeletalmusclerelaxants-151101095949-lva1-app6891 (1).pptxskeletalmusclerelaxants-151101095949-lva1-app6891 (1).pptx
skeletalmusclerelaxants-151101095949-lva1-app6891 (1).pptx
 
Neuromuscular junction pharmacology, drugs used
Neuromuscular junction pharmacology, drugs usedNeuromuscular junction pharmacology, drugs used
Neuromuscular junction pharmacology, drugs used
 

Mais de Carlos D A Bersot

Mais de Carlos D A Bersot (20)

Enhanced recovery after surgery in neurosurgery
Enhanced recovery  after surgery in neurosurgeryEnhanced recovery  after surgery in neurosurgery
Enhanced recovery after surgery in neurosurgery
 
Oximetria Cerebral
 Oximetria Cerebral Oximetria Cerebral
Oximetria Cerebral
 
Monitorização na área de radiologia intervencionista
Monitorização na área de radiologia intervencionistaMonitorização na área de radiologia intervencionista
Monitorização na área de radiologia intervencionista
 
Monitorizacao hemodinamica com Ecocardiograma
Monitorizacao hemodinamica com EcocardiogramaMonitorizacao hemodinamica com Ecocardiograma
Monitorizacao hemodinamica com Ecocardiograma
 
Neurofisiologia e edema cerebral COPA 13.04.pptx
Neurofisiologia e edema cerebral  COPA 13.04.pptxNeurofisiologia e edema cerebral  COPA 13.04.pptx
Neurofisiologia e edema cerebral COPA 13.04.pptx
 
Aula COPA 2022
Aula COPA 2022  Aula COPA 2022
Aula COPA 2022
 
Dor Crônica 2021
Dor Crônica 2021Dor Crônica 2021
Dor Crônica 2021
 
FATE POCUS .pptx
FATE POCUS .pptxFATE POCUS .pptx
FATE POCUS .pptx
 
Ultrassom pulmonar `POCUS
Ultrassom pulmonar `POCUSUltrassom pulmonar `POCUS
Ultrassom pulmonar `POCUS
 
Protocolo FAST POCUS
Protocolo  FAST POCUSProtocolo  FAST POCUS
Protocolo FAST POCUS
 
Acesso vascular POCUS
 Acesso vascular POCUS Acesso vascular POCUS
Acesso vascular POCUS
 
Fibroscopia para o anestesista
Fibroscopia  para o anestesistaFibroscopia  para o anestesista
Fibroscopia para o anestesista
 
Opioid-free anesthesia/ERAS
Opioid-free anesthesia/ERASOpioid-free anesthesia/ERAS
Opioid-free anesthesia/ERAS
 
Neuroanatomia da Dor/ Neuroanatomy of Pain
Neuroanatomia da Dor/ Neuroanatomy of PainNeuroanatomia da Dor/ Neuroanatomy of Pain
Neuroanatomia da Dor/ Neuroanatomy of Pain
 
Is the prone position indicated in critically ill patients with SARS-CoV- 2 d...
Is the prone position indicated in critically ill patients with SARS-CoV- 2 d...Is the prone position indicated in critically ill patients with SARS-CoV- 2 d...
Is the prone position indicated in critically ill patients with SARS-CoV- 2 d...
 
Peri-operative fluid management during neurosurgical procedures
Peri-operative fluid management during neurosurgical proceduresPeri-operative fluid management during neurosurgical procedures
Peri-operative fluid management during neurosurgical procedures
 
Infografico ketamina
Infografico ketamina Infografico ketamina
Infografico ketamina
 
Point of Care Pulmonar
 Point of Care Pulmonar Point of Care Pulmonar
Point of Care Pulmonar
 
FATE-Basic Cardiac Ultrasound I
FATE-Basic Cardiac Ultrasound IFATE-Basic Cardiac Ultrasound I
FATE-Basic Cardiac Ultrasound I
 
Curso de vias aéreas fármacos
  Curso de vias aéreas    fármacos  Curso de vias aéreas    fármacos
Curso de vias aéreas fármacos
 

Último

Call Girls in Gagan Vihar (delhi) call me [🔝 9953056974 🔝] escort service 24X7
Call Girls in Gagan Vihar (delhi) call me [🔝  9953056974 🔝] escort service 24X7Call Girls in Gagan Vihar (delhi) call me [🔝  9953056974 🔝] escort service 24X7
Call Girls in Gagan Vihar (delhi) call me [🔝 9953056974 🔝] escort service 24X7
9953056974 Low Rate Call Girls In Saket, Delhi NCR
 

Último (20)

All Time Service Available Call Girls Marine Drive 📳 9820252231 For 18+ VIP C...
All Time Service Available Call Girls Marine Drive 📳 9820252231 For 18+ VIP C...All Time Service Available Call Girls Marine Drive 📳 9820252231 For 18+ VIP C...
All Time Service Available Call Girls Marine Drive 📳 9820252231 For 18+ VIP C...
 
Call Girls Jaipur Just Call 9521753030 Top Class Call Girl Service Available
Call Girls Jaipur Just Call 9521753030 Top Class Call Girl Service AvailableCall Girls Jaipur Just Call 9521753030 Top Class Call Girl Service Available
Call Girls Jaipur Just Call 9521753030 Top Class Call Girl Service Available
 
Call Girls Rishikesh Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Rishikesh Just Call 8250077686 Top Class Call Girl Service AvailableCall Girls Rishikesh Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Rishikesh Just Call 8250077686 Top Class Call Girl Service Available
 
💕SONAM KUMAR💕Premium Call Girls Jaipur ↘️9257276172 ↙️One Night Stand With Lo...
💕SONAM KUMAR💕Premium Call Girls Jaipur ↘️9257276172 ↙️One Night Stand With Lo...💕SONAM KUMAR💕Premium Call Girls Jaipur ↘️9257276172 ↙️One Night Stand With Lo...
💕SONAM KUMAR💕Premium Call Girls Jaipur ↘️9257276172 ↙️One Night Stand With Lo...
 
Best Rate (Guwahati ) Call Girls Guwahati ⟟ 8617370543 ⟟ High Class Call Girl...
Best Rate (Guwahati ) Call Girls Guwahati ⟟ 8617370543 ⟟ High Class Call Girl...Best Rate (Guwahati ) Call Girls Guwahati ⟟ 8617370543 ⟟ High Class Call Girl...
Best Rate (Guwahati ) Call Girls Guwahati ⟟ 8617370543 ⟟ High Class Call Girl...
 
Coimbatore Call Girls in Thudiyalur : 7427069034 High Profile Model Escorts |...
Coimbatore Call Girls in Thudiyalur : 7427069034 High Profile Model Escorts |...Coimbatore Call Girls in Thudiyalur : 7427069034 High Profile Model Escorts |...
Coimbatore Call Girls in Thudiyalur : 7427069034 High Profile Model Escorts |...
 
Low Rate Call Girls Bangalore {7304373326} ❤️VVIP NISHA Call Girls in Bangalo...
Low Rate Call Girls Bangalore {7304373326} ❤️VVIP NISHA Call Girls in Bangalo...Low Rate Call Girls Bangalore {7304373326} ❤️VVIP NISHA Call Girls in Bangalo...
Low Rate Call Girls Bangalore {7304373326} ❤️VVIP NISHA Call Girls in Bangalo...
 
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...
 
Russian Call Girls Service Jaipur {8445551418} ❤️PALLAVI VIP Jaipur Call Gir...
Russian Call Girls Service  Jaipur {8445551418} ❤️PALLAVI VIP Jaipur Call Gir...Russian Call Girls Service  Jaipur {8445551418} ❤️PALLAVI VIP Jaipur Call Gir...
Russian Call Girls Service Jaipur {8445551418} ❤️PALLAVI VIP Jaipur Call Gir...
 
9630942363 Genuine Call Girls In Ahmedabad Gujarat Call Girls Service
9630942363 Genuine Call Girls In Ahmedabad Gujarat Call Girls Service9630942363 Genuine Call Girls In Ahmedabad Gujarat Call Girls Service
9630942363 Genuine Call Girls In Ahmedabad Gujarat Call Girls Service
 
VIP Hyderabad Call Girls Bahadurpally 7877925207 ₹5000 To 25K With AC Room 💚😋
VIP Hyderabad Call Girls Bahadurpally 7877925207 ₹5000 To 25K With AC Room 💚😋VIP Hyderabad Call Girls Bahadurpally 7877925207 ₹5000 To 25K With AC Room 💚😋
VIP Hyderabad Call Girls Bahadurpally 7877925207 ₹5000 To 25K With AC Room 💚😋
 
Call Girls in Gagan Vihar (delhi) call me [🔝 9953056974 🔝] escort service 24X7
Call Girls in Gagan Vihar (delhi) call me [🔝  9953056974 🔝] escort service 24X7Call Girls in Gagan Vihar (delhi) call me [🔝  9953056974 🔝] escort service 24X7
Call Girls in Gagan Vihar (delhi) call me [🔝 9953056974 🔝] escort service 24X7
 
Models Call Girls In Hyderabad 9630942363 Hyderabad Call Girl & Hyderabad Esc...
Models Call Girls In Hyderabad 9630942363 Hyderabad Call Girl & Hyderabad Esc...Models Call Girls In Hyderabad 9630942363 Hyderabad Call Girl & Hyderabad Esc...
Models Call Girls In Hyderabad 9630942363 Hyderabad Call Girl & Hyderabad Esc...
 
Call Girls Raipur Just Call 9630942363 Top Class Call Girl Service Available
Call Girls Raipur Just Call 9630942363 Top Class Call Girl Service AvailableCall Girls Raipur Just Call 9630942363 Top Class Call Girl Service Available
Call Girls Raipur Just Call 9630942363 Top Class Call Girl Service Available
 
Call Girls Service Jaipur {8445551418} ❤️VVIP BHAWNA Call Girl in Jaipur Raja...
Call Girls Service Jaipur {8445551418} ❤️VVIP BHAWNA Call Girl in Jaipur Raja...Call Girls Service Jaipur {8445551418} ❤️VVIP BHAWNA Call Girl in Jaipur Raja...
Call Girls Service Jaipur {8445551418} ❤️VVIP BHAWNA Call Girl in Jaipur Raja...
 
Call Girls Vasai Virar Just Call 9630942363 Top Class Call Girl Service Avail...
Call Girls Vasai Virar Just Call 9630942363 Top Class Call Girl Service Avail...Call Girls Vasai Virar Just Call 9630942363 Top Class Call Girl Service Avail...
Call Girls Vasai Virar Just Call 9630942363 Top Class Call Girl Service Avail...
 
Call Girls Hyderabad Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Hyderabad Just Call 8250077686 Top Class Call Girl Service AvailableCall Girls Hyderabad Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Hyderabad Just Call 8250077686 Top Class Call Girl Service Available
 
Manyata Tech Park ( Call Girls ) Bangalore ✔ 6297143586 ✔ Hot Model With Sexy...
Manyata Tech Park ( Call Girls ) Bangalore ✔ 6297143586 ✔ Hot Model With Sexy...Manyata Tech Park ( Call Girls ) Bangalore ✔ 6297143586 ✔ Hot Model With Sexy...
Manyata Tech Park ( Call Girls ) Bangalore ✔ 6297143586 ✔ Hot Model With Sexy...
 
Model Call Girls In Chennai WhatsApp Booking 7427069034 call girl service 24 ...
Model Call Girls In Chennai WhatsApp Booking 7427069034 call girl service 24 ...Model Call Girls In Chennai WhatsApp Booking 7427069034 call girl service 24 ...
Model Call Girls In Chennai WhatsApp Booking 7427069034 call girl service 24 ...
 
Call Girls Kolkata Kalikapur 💯Call Us 🔝 8005736733 🔝 💃 Top Class Call Girl Se...
Call Girls Kolkata Kalikapur 💯Call Us 🔝 8005736733 🔝 💃 Top Class Call Girl Se...Call Girls Kolkata Kalikapur 💯Call Us 🔝 8005736733 🔝 💃 Top Class Call Girl Se...
Call Girls Kolkata Kalikapur 💯Call Us 🔝 8005736733 🔝 💃 Top Class Call Girl Se...
 

Neuromuscular blocking

  • 1. NEUROMUSCULAR BLOCKING AGENTS Carlos Darcy Alves Bersot TSA.SBA MD RESPONSÁVEL PELO CET H.F.LAGOA Médico Anestesiologista do Hospital Federal da Lagoa-SUS Médico Anestesiologista do Hospital Pedro Ernesto-UERJ
  • 2. Key Concepts •Muscle relaxation does not ensure unconsciousness, amnesia, or analgesia •Neuromuscular blocking agents are used to improve conditions for tracheal intubation, to provide immobility during surgery, and to facilitate mechanical ventilation. •Depolarizing muscle relaxants act as acetylcholine (ACh) receptor agonists, whereas nondepolarizing muscle relaxants function as competitive antagonists. •Depolarizing muscle relaxants are not metabolized by acetylcholinesterase, they diffuse away from the neuromuscular junction and are hydrolyzed in the plasma and liver by another enzyme, pseudocholinesterase (nonspecific cholinesterase, plasma cholinesterase, or butyrylcholinesterase). •With the exception of mivacurium, nondepolarizing agents are not significantly metabolized by either acetylcholinesterase or pseudocholinesterase. Reversal of their blockade depends on redistribution, gradual metabolism, and excretion of the relaxant by the body, or administration of specific reversal agents (eg, cholinesterase inhibitors) that inhibit acetylcholinesterase enzyme activity. •Compared with patients with low enzyme levels or heterozygous atypical enzyme in whom blockade duration is doubled or tripled, patients with homozygous atypical enzyme will have a very long blockade (eg, 4–6 h) following succinylcholine administration. •Succinylcholine is considered contraindicated in the routine management of children and adolescents because of the risk of hyperkalemia, rhabdomyolysis, and cardiac arrest in children with undiagnosed myopathies
  • 3. •Normal muscle releases enough potassium during succinylcholine-induced depolarization to raise serum potassium by 0.5 mEq/L. Although this is usually insignificant in patients with normal baseline potassium levels, a life-threatening potassium elevation is possible in patients with burn injury, massive trauma, neurological disorders, and several other conditions •Doxacurium, pancuronium, vecuronium, and pipecuronium are partially excreted by the kidneys, and their action is prolonged in patients with renal failure. •Atracurium and cisatracurium undergo degradation in plasma at physiological pH and temperature by organ-independent Hofmann elimination. The resulting metabolites (a monoquaternary acrylate and laudanosine) have no intrinsic neuromuscular blocking effects •Hypertension and tachycardia may occur in patients given pancuronium. These cardiovascular effects are caused by the combination of vagal blockade and catecholamine release from adrenergic nerve endings •Long-term administration of vecuronium to patients in intensive care units has resulted in prolonged neuromuscular blockade (up to several days), possibly from accumulation of its active 3-hydroxy metabolite, changing drug clearance, or the development of a polyneuropathy •Rocuronium (0.9–1.2 mg/kg) has an onset of action that approaches succinylcholine (60–90 s), making it a suitable alternative for rapid-sequence inductions, but at the cost of a much longer duration of action.
  • 4.
  • 5.
  • 6. History of neuromuscular blocking agents • Early 1800’s – curare • 1942 – curare used for discovered in use by muscular relaxation in South American general anesthesia Indians as arrow • 1949 – gallamine poison discovered as a • 1932 – West substitute for curare employed curare in • 1964 – more potent patients with tetanus drug pancuronium and spastic disorders synthesized
  • 7. Bloqueadores Não-despolarizantes Curares - Chondrodendron e Strychnos Farmacologia – Texto e atlas, 4ª ed., 2003. Strychnos toxifera
  • 9. Milestones of Neuromuscular Blockade in Anesthesia • 1942 introduction of dTc in anesthesia • 1949 Succinylcholine, gallamine metocurine introduced • 1958 Monitoring of NMF with nerve stimulators • 1968 Pancuronium • 1971 introduction of TOF • 1982 Vecuronium,Pipecurium,atracurium • 1992 Mivacurium • 1994 Rocuronium • 1996 Cisatracurium • 2000 Rapacurium introduced and removed
  • 11. Aspectos Morfológicos e Funcionais Imagem da junção Sinapse neuromuscular imagem em microscopia eletrônica neuromuscular em varredura
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.
  • 22.
  • 23. α 2βγδ (embrionário) α 2βεδ (maduro) Only the two identical α subunits are capable of binding ACh molecules
  • 24. Neuromuscular Physiology Acetylcholine receptor channels Extrajunctional Junctional Anesthesia 5th ed p 740
  • 25.
  • 26. Bloqueadores Não-despolarizante MECANISMO DE AÇÃO Tubocurarine Potenciais de ação e potenciais de placa terminal na vigência de bloqueador não-despolarizante
  • 27. Bloqueadores Não-despolarizante Margem de Segurança da Transmissão Neuromuscular
  • 28.
  • 29. Site of Action of d-Tubocurarine Nerve AP Muscle AP Left Leg Muscle Stimulation Right Leg Nerve Stimulation Right Leg Muscle Stimulation
  • 33.
  • 34. Farmacologia da Junção Neuromuscular Bloqueadores Não-despolarizantes COMPOSTOS SINTÉTICOS Derivados Isoquinolínicos Lee, (2003) Pharmacology & Therapeutics, 98:143-169
  • 35. Farmacologia da Junção Neuromuscular Bloqueadores Não-despolarizantes COMPOSTOS SINTÉTICOS Derivados Aminoesteróides Lee, (2003) Pharmacology & Therapeutics, 98:143-169
  • 36. Farmacologia da Junção Neuromuscular Bloqueadores Despolarizantes Paton & Zaimis, 1949 – Decametônio e Succinilcolina Lee, (2003) Pharmacology & Therapeutics, 98:143-169
  • 37. Succinylcholine “Except when used for emergency tracheal intubation or in instances in clinical practice where immediate securing of the airway is necessary, succinylcholine is contraindicated in children and adolescent patients.”
  • 38. Succinylcholine Advantages Disadvantages Rapid onset Hyperkalemia (burns,massive trauma,denervation.…) Short Duration I.M. injection Cardiac Dysrhythmias Masseter Spasm Malignant Hyperthermia Myalgias Prolonged effect
  • 39. Succinylcholine: Hyperkalemic Response Major burns, Massive trauma, Denervation injuries prolonged immobility, sepsis. – normal response; approx. 0.5 mEq/L – not attenuated by defasciculation – increased extrajunctional receptors (few days to form)
  • 40.
  • 41. Succinylcholine: Myalgias • mechanism-speculative • incidence: 0.2-89% • young, female, early ambulation • severity not related to intensity of fasciculations • Pre-treatment with NDMR prevents fasciculations and may decrease myalgias
  • 42. Succinylcholine: increased intragastric pressure – G-E junction opens at pressures > 28cm H20 – transient increase up to 40 cm H20 – Defasciculate, abolishes the rise
  • 43. Succinylcholine: intraocular pressure – Prevention: defasciculate, benzodiazepam, lidocaine,acetazolamide, deep anesth. at laryngoscopy – Drug of Choice? for the “Glaucoma” and “full stomach” – Recommendations: SUX if possible, priorize, Airway first. – If SUX is used: sedate and defasciculate – transient increase of 8mm Hg ; peaks at 2-4 min – due to contraction of extra-ocular muscles • See Vachon C. Succinylcholine and the open globe: Tracing the Teaching Anesthesiol 99: 220-223, 2003
  • 44. Succinylcholine: Prolonged Apnea after…. • Etiology • Diagnosis • Management
  • 45. Prolonged Apnea after Succinylcholine Etiology • Decreased Plasma Cholinesterase Activity – Physiologic Variation – Disease States – Iatrogenic – Genetic
  • 46. Duration of Sux induced NM-block VS pChE activity Anesthesia 5th ed p 420
  • 47. Plasma Cholinesterase (Prolonged Apnea after….) • Disease States – Hepatic Cirrhosis (reduced 50%) – renal disease (50%), returns to normal after renal transplant – malignancy (bronchogenic, GI) – Burns
  • 48. Plasma Cholinesterase (Prolonged Apnea after…) • Iatrogenic – echthiophate – anticholinesterases – pancuronium – pheneizine (MAO inhibitor) – glucocorticoids (estrogens) – organophosphates (insecticides) – cytotoxic drugs (cyclophosphamide)
  • 49. Malignant Hyperthermia (Hyperpyrexia) • Condition caused by a defect in the molecule linking muscle membrane t-tubules to the sarcoplasmic reticulum (ryanodine receptor). • Uncontrolled Ca++ release from the S.R. leads to contracture and a rise in body core temperature. • Succinylcholine can precipitate an attack even in the absence of halothane like anesthetics. • Dantrolene blocks this inappropriate response of the ryanodine receptor and prevents Ca++ loss
  • 50. Muscle Relaxants: Physio-chemical Properties Highly Ionized at Physiol. pH – + charged quaternary N attracted to - charged cholinergic receptor – most contain 2 + charges (biquaternary) separated by varying sizes of lipophilic bridge (potency) – quaternary ammonium (like Ach)
  • 51. Muscle Relaxants: Physio-chemical Properties Highly Water Soluble/ Relatively Hydrophilic – easily excreted in urine – do not cross lipid membranes (most cells, BBB, placenta) – small volume of distribution – not actively metabolized by the liver (cytochrome P-450 enzyme system requires lipophilic substrates)
  • 52. Pancuronium • Bis-quaternary Aminosteroid • High potency therefore slow onset • Long acting • No or slight increase on blood pressure • Vagolytic • Renal clearance
  • 53. Rocuronium Mono-quaternary aminosteroid – potency, approx 1/6 that of Vecuronium – fast onset (< I min with 0.8 mg/kg) – intermediate duration (44 min with 0.8 mg/kg) – minimal CV side effects – onset and duration prolonged in elderly – slight decrease in elimination in RF
  • 54. Mivacurium Bisquaternary benzylisoquinoline – potency, 1/3 that of atracurium – relatively slow onset 1.5 min with 0.25 mg/kg – short duration 12-18 min with 0.25 mg/kg – histamine release with doses 3-4X ED95 – hydrolyzed by pChE, recovery may be prolonged in some populations (e.g. atypical pChE)
  • 55. Cis-Atracurium one of the stereo isomers of atracurium (15%) – 3 X more potent than atracurium – slow onset, intermediate duration – eliminated by Hoffman degradation – Laudanosine as a metabolite – non-organ elimination – doses of 5 X ED95 (0.05mg/kg) • no histamine release • CV stability
  • 56. Rapacuronium monoquaternary aminosteroid, analogue of Vecuronium – low potency, fast onset, short to intermediate duration – 1.5-2.0 mg/kg doses give good intubating conditions at 60 sec – duration of action, dependent on dosage and age of patient – 20 % decrease in aBP observed with 2-3 mg/kg doses – principle route of elimination may be liver as 22% is renal excretion. – introduced in 2000 in US and removed, after paediatric deaths (bronchospasm).
  • 57.
  • 58. Hemodynamic Effects of d-Tubocurarine and Pancuronium HR CO SVR MAP
  • 59. Effect of Potency on Onset of NMB
  • 60. Effect of Dose on Onset of NMB
  • 61. Hepato-Biliary Disease Pancuronium (20% metabolized to active metabolite) increased Vd decreased plasma clearance prolonged elimination T1/2 A large initial dose is required to prod the same plasma conc. but the block will be prolonged Vecuronium (20-30%metabolized to active metabolite) initial studies yielded similar results to pancuronium later studies show effect only with large doses Rocuronium is excreted unchanged in the urine and bile. Biliary excretion (2/3) appears to the predominant route. In cirrhotic patients, rocuronium pharmacodynamics and elimination kinetics are not changed much. The prolonged onset and slightly prolonged recovery is explained by the larger Vd in these patients.
  • 62. Percent of Dose Dependant on Renal Elimination > 90% 60-90% 40-60% <25% Gallamine (97) Pancuronium (80) d-TC (45) Succinylcholine Pipecuronium (70) Vecuronium (20) Doxacurium (70) Atracurium (NS) Metocurine (60) Mivacurium (NS) Rocuronium
  • 63. Rationale Choice of Muscle Relaxant: Cardiovascular Effects Tachycardia Bradycardia Hypotension Arrhythmias
  • 64. Reversal of Neuromuscular Blockade How? • Anticholinesterases: – Edrophonium – Neostigmine • Cholinesterase • Removal of blocking agents – Org 25969 (Cylcodextrin) • Ring of sugars that soak up Rocuronium •
  • 65. Anticholinesterases Unwanted side effects – Autonomic – Nausea and vomiting • Neostigmine > Edrophonium ? • Edrophonium (0.5-1.0 mg/kg) with Atropine ( 7-15 ug/kg) • Neostigmine (40-70 ug/kg) with Glycopyrolate (0.7-1.0mg)
  • 66. Difficulty reversing block • Right dose? • Intensity of block to be reversed? • Choice of relaxant? • Age of patient? • Acid-base and electrolyte status? • Temperature? • Other drugs?
  • 67. Cold patients-longer durations Anesthesia 5th ed p 463
  • 68. POSTOPERATIVE RESIDUAL CURARIZATION ( PORC) • common after NDMRs • long acting > intermediate > short acting • Assoc with respir. morbidity • not observed in children • monitoring decreases incidence
  • 69. Ventilatory response to hypoxia is impaired and does not return to normal until TOF > 0.9 (Ericksson et al, Anesthesiology 78: 693-699 1993) • Reduced Pharyngeal muscle coordination with TOF 0.6-.08 (Ericksson et al, Anesthesiology 87: 1035-43 1997)
  • 70.
  • 72. Approximate Relationships of % receptor blockade, ST and TOF with NDMB Total receptors Single twitch, T1 Train of Four, T4 T4/T1 Blocked % % normal % Normal 100 0 0 90-95 0 0 T1 lost 85-90 10 0 T2 lost 20 0 T3 lost 80-85 25 0 T4 lost 80-90 48-58 0.6-0.7 95 69-79 0.7-0.75 75 100 75-100 0.75-1.0 100 100 0.9-1.0 50 100 100 1.0 25 100 100 1.0
  • 73. Monitoring Neuromuscular Function • Visual/tactile assessment of evoked responses • Measurement of evoked responses • Mechanomyography • Electromyography • Accelerometry
  • 74. Monitoring Neuromuscular Function • Mechanomyography – Gold standard
  • 75. Monitoring Neuromuscular Function • Accelerometry
  • 76.
  • 77. Monitoring Neuromuscular Function SUPRAMAXIMAL STIMULATION – 10-20% above current output required to stimulate all nerve fibers – Minimizes influence of :temp.skin resistance and changes in electrode conductance
  • 78. Monitoring Neuromuscular Function • STIMULATION PATTERNS • Single Impulse or Twitch (ST) • Train of Four (TOF) • Tetanus • Double Burst Simulation (DBS) • Post Tetantic Count (PTC)
  • 79. STIMULATION PATTERNS • SINGLE TWITCH – Onset, dependency on frequency – Recovery • Control required • May still have residual paralysis
  • 80. STIMULATION PATTERNS • TETANUS – 50 Hz, fade with NDMR’s – 100 Hz, fade without NDMR’s – Sensitive indicator of residual block
  • 81. SIMULATION PATTERNS • TRAIN OF FOUR (TOF) – Measures continued relaxation – Identifies phase II block – No control required – Tolerable in awake patients – measurement O.7 of o.9 or 1 ????
  • 82. STMULATION PATTERNS • DOUBLE BURST STIMULATION – Two bursts of 50Hz stimulation, separated by 750msec – Measured fade correlates with TOF – Tactile and visual evaluation of response superior to TOF
  • 83. STIMULATION PATTERNS • POST TETANIC COUNT – 50 Hz for 5 sec, followed in 3 sec by ST@ 1 Hz – Shouldn’t be repeated more than 6 mins – Used to monitor intense block – Predicts optimal time to reversal

Notas do Editor

  1. As principais substâncias que promovem o bloqueio pós-juncional por competição são os alcalóides do curare, provenientes de plantas do gênero Chondrodendron e Strychnos. Esses compostos apresentam grande valor histórico, pois o curare são e foram compostos utilizados pelos índios para a captura de suas prezas, sendo extraídos dessas plantas e utilizados nas pontas de flechas. Como apresentavam ação paralizante da presa, o interesse por cientistas da época foi grande. E
  2. A margem de segurança da transmissão neuromuscular nos permite avaliar o quanto a transmissão neuromuscular esta comprometida, no gráfico acima temos nas ordenadas a força de contração do músculo, sendo todas relativas ao registro inicial; nas abscissas encontra-se a fração de receptores bloqueados. Logo quanto maior a concentração do bloqueador competitivo, maior será a fração de receptores bloqueados, até chegar a um ponto em que a transmissão neuromuscular começa a ficar compromotida, no exemplo acima temos vários tipos de preparações e pode-se notar que a partir de 75% de bloqueio a preparações começam a apresentar o comprometimento da transmissão. Isso é muito importante no processo cirúrgico, pois o paciente pode apresentar certo grau de bloqueio mesmo sem apresentar comprometimento da transmissão, consequentemente uma dose adicional inadequada pode promover sérios efeitos (como bloqueio prolongado).
  3. Temos também o outro grupo de bloquedores neuromusculares, que são os bloqueadores despolarizantes. Esses foram descobertos por Burns e Paton em 1951, sendo o primeiro o Decametônio; esses compostos apresentam estrutura semelhante a acetilcolina e apresentam uma ação de agonista estável, ou seja são capazes de interagir com o receptor (pois apresentam afinidade), no entanto, possuem pouca atividade.
  4. Five years ago, a letter from Burroughs Wellcome containing this statement was sent to all anesthesiologists in Canada and the US. This was followed by a deluge of protest, so great that the company replaced the “contraindication” with a warning of the rare possibility of inducing life-threatening hyperkalemia in infants and children with undiagnosed myopathies. No other drug used in anesthesia is associated with such a high incidence of complications yet continues to be used 54 yrs after its introduction. The second is an anonymous quote but heard quite often
  5. Complications assoc with Succ which present or persist into the PACU: Muscle pains Myoglobinaemia Myoglobinuria Hyperkalemia Phase II block Reduced pChE Malignant hyperthermia Anaphylaxis Often asked question: What are the contraindications to succinylcholine?
  6. Vulnerable periods for Sux induced hyperkalemia: Spinal cord injuries: 24hrs to 6 months Burns:7days to 1 year
  7. mechanism: reversible damage to muscle fibers caused by shearing stresses from the uncoordinated activation of individual muscle fibers is one possible explanation many suggestions to reduce or prevent fasciculations, myalgias and muscle damage: Pretreat with an NDMR, a “taming dose of Succ,benzodiazepine, lidocaine,fentanyl, MgSo4, dantrolene, Vitamin C, and Ca gluconate. Defasciculation. is probably the most reliable.-but watch out for the sensitive patient! One recent doubled blinded, randomised control study showed no difference in the incidence of myalgias comparing sux (after defasciculation with dTC) and mivacurium.
  8. We would expect a blocking agent to possess a positive charge with an affinity for the complementary negative charge on the Ach receptor. It is a fact that all clinically useful NM blocking agents bear a positively charged N. At least one quaternary N is necessary to achieve high potency, by confirming the drug within a very restrictive volume of distribution An increase in the size of the N substituents leads to a decrease in depolarizing activity and generally some decrease in potency.
  9. Mivacurium: Advantages: 1) short cases,2) facility with infusion Disadvantages: 1) slow onset ( can be shortened with priming) 2) hypotension with large doses, or when given quickly (less than 30 sec), 3) prolonged duration in susceptible population.
  10. It still has landanosine as one of its bi-products of spontaneous degradation but because it is more potent
  11. This is a series of aminosteriods with different potencies. Agents with low potencies &lt;100 ug/kg have feaster onsets. The asymtope is at approx 90-100 sec. So even with less potent agents we may not do any better than 90-100 sec
  12. Onset of NM block can be increased by administering a larger dose. The typical intubating dose is about 2.5 -3 X the ED 95 of that particular agent. By using an even larger dose onset time can be further reduced but this has an expense and that is a longer duration of action.
  13. In renal failure patients, the elimination kinetics were slightly decreased for Rocuronium
  14. Edrophonium and neostigmine are both Quaternary Ammonium cpds\\ Edrophonium: Predominant site of action is presynaptic. Does have mild muscarinic effects. Because of its short duration of action in small doses (e.g. 1 mg) useful in Dx of Myasthenia Crisis vs Cholinergic crisis.Dosing requirements same for children and adults but higher doses needed for elderly Neostigmine: Predominant effect is post-synaptic. Renal clearance is 50% Hepatic clearance 50%, Inactive metabolites. Time course of onset and duration produced by an equipotent does of neostigmine similar in adults and children but dose is less for children
  15. It is going to be difficult to reverse a block induced with Doxacurium in “cold”and hypokalemic 80 year old on an aminoglycoside with barely one twitch with O.3 mg/kg of Edrophonium Factors prolonging NMB: Deficiency or atypical pseudocholinesterase, Hypermagnesemia,Hypothermia,Respiratory acidosis, Hypokalemia, Antibiotics
  16. POST OPERATIVE RESIDUAL CURIZATION OR PARALYSIS Is a common problem especially with long acting agents Until recently the standard was TOF &gt; 0.7 . This value was derived from “awake unanesthetized volunteers who had sign. decreases in measured FVC and max inspiratory pressures. It now appears that a TOF of &gt;0.9 is needed to assure complete recovery from NMB, since we now know that even small degrees of block may modify respiratory response to hypoxia and predispose to aspiration!
  17. Erickson in 1993 showed decreased hypoxic drive in subjects given vecuronium to reduce the TOF to &lt;0.7 but had a normal response when TOF &gt; 0.9 Again Erickson in 1997 demonstrated in volunteers impaired swallowing and aspiration with TOF as high as0.9
  18. Sensitive to variations in current,temperature and tension preload Cannot distinguish between non-depolarizing and depolarizing block Presence of full twitch does not guarantee full recovery
  19. 100 Hz not physiological
  20. Four supramaximal stimuli given every 0.5 sec May be repeated to more than every 10-12 sec Each stimuli after the first causes contraction, with fade giving basis for evaluation Provides useful correlation of fade and clinical NM block. Fade can be visualized, felt or measured. But it is difficult to assess fade visually or by tactile means. Cannot monitor deep NM block
  21. In non-paralyzed muscle, response is two short contractions of equal strength. In partly paralyzed muscle the second response is weaker
  22. Potentiation of facilitation of contractions is seen after tetanic simulation when muscle relaxants are onboard. There is more Ach competing for receptor sites with the neuromuscular blocker. This is seen with NDMR’s but can also be observed in Phase II block induced with succinylcholine. Magnitude is a function of the depth of block.